

Peroxisome proliferator-activated receptor- γ ligands a

Cancer Treatment Reviews

30, 545-554

DOI: [10.1016/j.ctrv.2004.04.004](https://doi.org/10.1016/j.ctrv.2004.04.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ligands for the peroxisome proliferator-activated receptor- β have inhibitory effects on growth of human neuroblastoma cells in vitro. <i>Toxicology</i> , 2005, 213, 157-168.	2.0	31
2	Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?. <i>Biochemical Pharmacology</i> , 2005, 70, 177-188.	2.0	251
3	PPAR β -dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF). <i>International Journal of Cancer</i> , 2005, 117, 923-933.	2.3	54
4	Peroxisome proliferator activated receptor- β ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 400-408.	1.1	46
5	Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. <i>Biomarkers</i> , 2005, 10, 295-309.	0.9	51
6	Peroxisome proliferator-activated receptor- β ligands for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 557-568.	1.9	74
7	The peroxisome proliferator-activated receptor β ligand troglitazone induces apoptosis and p53 in rat granulosa cells. <i>Molecular and Cellular Endocrinology</i> , 2005, 233, 15-24.	1.6	39
8	Peroxisome proliferator-activated receptors (PPARs) and ovarian function—implications for regulating steroidogenesis, differentiation, and tissue remodeling. <i>Reproductive Biology and Endocrinology</i> , 2005, 3, 41.	1.4	178
9	Potential therapeutic role of peroxisome proliferator activated receptor- β agonists in psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1455-1461.	0.9	9
10	Cellular, Molecular Consequences of Peroxisome Proliferator- Activated Receptor- β Activation in Ovarian Cancer Cells. <i>Neoplasia</i> , 2006, 8, 851-862.	2.3	48
11	Proline Oxidase, a Proapoptotic Gene, Is Induced by Troglitazone. <i>Journal of Biological Chemistry</i> , 2006, 281, 2044-2052.	1.6	99
12	Carbon Monoxide Orchestrates a Protective Response through PPAR β . <i>Immunity</i> , 2006, 24, 601-610.	6.6	146
13	Differential modulation of cell cycle, apoptosis and PPAR β 2 gene expression by PPAR β agonists ciglitazone and 9-hydroxyoctadecadienoic acid in monocytic cells. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2006, 74, 283-293.	1.0	32
14	From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. <i>Progress in Lipid Research</i> , 2006, 45, 120-159.	5.3	656
15	PPAR β is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1801-1811.	2.2	53
16	The cell cycle as a therapeutic target for Alzheimer's disease. , 2006, 111, 99-113.		85
17	Effects of PPAR β agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 1021-1035.	1.2	27
18	Expression of peroxisome proliferator activated receptor β and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. <i>Journal of Clinical Pathology</i> , 2006, 60, 307-310.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Effects of luteinizing hormone on peroxisome proliferator-activated receptor $\hat{1}\beta$ in the rat ovary before and after the gonadotropin surge. <i>Reproduction</i> , 2006, 131, 93-101.	1.1	16
20	Thiazolidinediones Ameliorate Diabetic Nephropathy via Cell Cycle-Dependent Mechanisms. <i>Diabetes</i> , 2006, 55, 1666-1677.	0.3	93
21	Lipid Phosphate Phosphatase-2 Activity Regulates S-phase Entry of the Cell Cycle in Rat2 Fibroblasts. <i>Journal of Biological Chemistry</i> , 2006, 281, 9297-9306.	1.6	35
22	Peroxisome Proliferator-activated Receptor- $\hat{1}\beta$ Is Dephosphorylated and Degraded during BAY 11-7085-induced Synovial Fibroblast Apoptosis. <i>Journal of Biological Chemistry</i> , 2006, 281, 22597-22604.	1.6	15
23	Peroxisome proliferator-activated receptor- $\hat{1}\beta$ ligands as investigational modulators of angiogenesis. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1561-1572.	1.9	28
24	Regulators of the G1 Phase of the Cell Cycle and Neurogenesis. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2007, 7, 115-128.	0.5	0
25	Activation of Peroxisome Proliferator-Activated Receptor $\hat{1}\beta$ (PPAR $\hat{1}\beta$) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in Vivo. <i>Endocrinology</i> , 2007, 148, 903-911.	1.4	130
26	Effects of Thiazolidinediones on Differentiation, Proliferation, and Apoptosis. <i>Molecular Cancer Research</i> , 2007, 5, 523-530.	1.5	61
27	Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor- $\hat{1}\alpha$, CH11 and CYC202. <i>Endocrine-Related Cancer</i> , 2007, 14, 305-315.	1.6	29
28	Energy Balance, Myostatin, and GILZ: Factors Regulating Adipocyte Differentiation in Belly and Bone. <i>PPAR Research</i> , 2007, 2007, 1-12.	1.1	9
29	Effects of dietary retinoids and carotenoids on immune development. <i>Proceedings of the Nutrition Society</i> , 2007, 66, 458-469.	0.4	72
30	Cytotoxicity of peroxisome proliferator-activated receptor $\hat{1}\alpha$ and $\hat{1}\beta$ agonists in renal proximal tubular cell lines. <i>Toxicology in Vitro</i> , 2007, 21, 1066-1076.	1.1	12
31	PPAR $\hat{1}\beta$ activation abolishes LDL-induced proliferation of human aortic smooth muscle cells via SOD-mediated down-regulation of superoxide. <i>Biochemical and Biophysical Research Communications</i> , 2007, 359, 1017-1023.	1.0	19
32	A consideration of PPAR- $\hat{1}\beta$ ligands with respect to lipophilicity: current trends and perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 413-417.	1.9	17
33	Peroxisome proliferator-activated receptor- $\hat{1}\beta$ ligands as bone turnover modulators. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 195-207.	1.9	11
34	Continuous Nucleocytoplasmic Shuttling Underlies Transcriptional Activation of PPAR $\hat{1}\beta$ by FABP4. <i>Biochemistry</i> , 2007, 46, 6744-6752.	1.2	128
35	Investigation of the lipophilic behaviour of some thiazolidinediones. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 857, 181-187.	1.2	24
36	Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 231-244.	1.0	50

#	ARTICLE	IF	CITATIONS
37	Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor- γ agonists induced apoptosis in human monocyte leukemia cells in vitro. <i>Annals of Hematology</i> , 2007, 86, 173-183.	0.8	29
38	Expression of Peroxisome Proliferator-Activated Receptor- γ in Colon Cancer: Correlation with Histopathological Parameters, Cell Cycle-Related Molecules, and Patients' Survival. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2305-2311.	1.1	40
39	Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome. <i>Current Atherosclerosis Reports</i> , 2007, 9, 222-229.	2.0	31
40	Heme oxygenase and carbon monoxide initiate homeostatic signaling. <i>Journal of Molecular Medicine</i> , 2008, 86, 267-279.	1.7	207
41	Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells. <i>Molecular Carcinogenesis</i> , 2008, 47, 905-915.	1.3	16
42	Quantitative Structure-Activity Relationships for PPAR- γ Binding and Gene Transactivation of Tyrosine-Based Agonists Using Multivariate Statistics. <i>Chemical Biology and Drug Design</i> , 2008, 72, 257-264.	1.5	15
43	Peroxisome proliferator-activated receptor- γ and growth inhibition by its ligands in prostate cancer. <i>Cancer Detection and Prevention</i> , 2008, 32, 259-266.	2.1	25
44	The prince and the pauper. A tale of anticancer targeted agents. <i>Molecular Cancer</i> , 2008, 7, 82.	7.9	73
45	Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 179-197.	1.0	72
46	PPAR- γ signaling pathway in placental development and function: A potential therapeutic target in the treatment of gestational diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1049-1063.	1.5	22
47	Osteogenic and Adipogenic Induction Potential of Human Periodontal Cells. <i>Journal of Periodontology</i> , 2008, 79, 525-534.	1.7	43
48	Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. <i>British Journal of Nutrition</i> , 2008, 99, ES78-ES108.	1.2	84
49	PPAR- γ is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. <i>Carcinogenesis</i> , 2008, 29, 1407-1414.	1.3	57
50	The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products. <i>PPAR Research</i> , 2008, 2008, 1-15.	1.1	20
51	Peroxisome Proliferator-Activated Receptor- γ ; (PPAR- γ) Ligands: Novel Pharmacological Agents in the Treatment of Ischemia Reperfusion Injury. <i>Current Molecular Medicine</i> , 2008, 8, 562-579.	0.6	39
52	Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?. <i>Journal of Hypertension</i> , 2008, 26, 973-980.	0.3	32
53	The Role of PPARs in Cancer. <i>PPAR Research</i> , 2008, 2008, 1-15.	1.1	190
54	PPAR Ligands as Antitumorigenic and Antiangiogenic Agents. <i>PPAR Research</i> , 2008, 2008, 1-8.	1.1	27

#	ARTICLE	IF	CITATIONS
55	Peroxisome Proliferator-Activated Receptor- γ Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. PPAR Research, 2008, 2008, 1-12.	1.1	29
56	Ciglitazone, an agonist of peroxisome proliferator-activated receptor γ , exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin. International Journal of Oncology, 2008, , .	1.4	2
57	PPAR- γ Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer. PPAR Research, 2009, 2009, 1-18.	1.1	92
58	Structural Basis for the Design of PPAR- γ Ligands: A Survey on Quantitative Structure-Activity Relationships. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1075-1083.	1.1	8
59	Antitumor activity of a novel series of γ -aryloxy- γ -methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines. Investigational New Drugs, 2009, 27, 223-232.	1.2	9
60	Peroxisome proliferator-activated receptor- γ (PPAR- γ) ligands as potential therapeutic agents to treat arthritis. Pharmacological Research, 2009, 60, 160-169.	3.1	58
61	Peroxisome Proliferator-Activated Receptor- γ Agonists Promote Differentiation and Antioxidant Defenses of Oligodendrocyte Progenitor Cells. Journal of Neuropathology and Experimental Neurology, 2009, 68, 797-808.	0.9	88
62	Therapeutic Implications of PPAR- γ in Human Osteosarcoma. PPAR Research, 2010, 2010, 1-16.	1.1	43
63	Association between peroxisome proliferator-activated receptor- γ gene polymorphism (Pro12Ala) and Helicobacter pylori infection in gastric carcinogenesis. Scandinavian Journal of Gastroenterology, 2010, 45, 1162-1167.	0.6	14
64	PPARs and Myocardial Response to Ischemia in Normal and Diseased Heart. , 2011, , 135-148.		1
66	PPAR- γ : A molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation, 2011, 82, 220-236.	1.0	41
67	Adriamycin inhibits adipogenesis through the modulation of PPAR- γ and restoration of adriamycin-mediated inhibition of adipogenesis by PPAR- γ over-expression. Toxicology Mechanisms and Methods, 2012, 22, 540-546.	1.3	26
68	Synthesis, Characterization and Biological Evaluation of Ureidofibrate-Like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor Activity. Journal of Medicinal Chemistry, 2012, 55, 37-54.	2.9	46
69	Aminoacylase 1-catalysed deacetylation of bioactives epoxides mycotoxin-derived mercapturates; 3,4-epoxyprococenes as models of cytotoxic epoxides. Biochimie, 2012, 94, 1668-1675.	1.3	7
70	Expression of Peroxisome Proliferator Activated Receptor-Gamma (PPAR- γ) in Human Non-small Cell Lung Carcinoma: Correlation with Clinicopathological Parameters, Proliferation and Apoptosis Related Molecules and Patients's Survival. Pathology and Oncology Research, 2012, 18, 875-883.	0.9	29
71	The role of PPAR in myocardial response to ischemia in normal and diseased heart. General Physiology and Biophysics, 2012, 30, 329-341.	0.4	30
72	Restoration of C/EBP- β in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis. Genes Chromosomes and Cancer, 2012, 51, 313-327.	1.5	22
73	Efatutazone, an Oral PPAR- γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2392-2400.	1.8	99

#	ARTICLE	IF	CITATIONS
75	Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based caseâ€“control study. <i>BMC Cancer</i> , 2013, 13, 420.	1.1	5
76	Interplay between SOX9, β -catenin and PPAR γ activation in colorectal cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 1853-1865.	1.9	36
77	The PPAR γ Agonist Efatutazone Increases the Spectrum of Well-Differentiated Mammary Cancer Subtypes Initiated by Loss of Full-Length BRCA1 in Association with TP53 Haploinsufficiency. <i>American Journal of Pathology</i> , 2013, 182, 1976-1985.	1.9	19
78	Doinseunggítang Ameliorates Endothelial Dysfunction in Diabetic Atherosclerosis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-10.	0.5	6
79	The anti-tumor activity of Mikania micrantha aqueous extract in vitro and in vivo. <i>Cytotechnology</i> , 2014, 66, 107-117.	0.7	16
80	5-Ethoxymethylidene-4-thioxo-2-thiazolidinone as Versatile Building Block for Novel Biorelevant Small Molecules with Thiopyrano[2,3- <i>d</i>][1,3]thiazole Core. <i>Synthetic Communications</i> , 2014, 44, 237-244.	1.1	28
81	Identification of transcription factors for drug-associated gene modules and biomedical implications. <i>Bioinformatics</i> , 2014, 30, 305-309.	1.8	27
82	Combined Treatment with Troglitazone and Lovastatin Inhibited Epidermal Growth Factor-Induced Migration through the Downregulation of Cysteine-Rich Protein 61 in Human Anaplastic Thyroid Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0118674.	1.1	15
83	Protective Effects of <i>Turbinaria ornata</i> and <i>Padina pavonia</i> against Azoxymethane-Induced Colon Carcinogenesis through Modulation of PPAR Gamma, NF- κ B and Oxidative Stress. <i>Phytotherapy Research</i> , 2015, 29, 737-748.	2.8	22
84	Differential ontogenetic exposure to obesogenic environment induces hyperproliferative status and nuclear receptors imbalance in the rat prostate at adulthood. <i>Prostate</i> , 2016, 76, 662-678.	1.2	10
85	Intestinal PPAR γ signalling is required for sympathetic nervous system activation in response to caloric restriction. <i>Scientific Reports</i> , 2016, 6, 36937.	1.6	20
86	Genotoxic investigation of a thiazolidinedione PPAR γ agonist using their vitromicronucleus test and their vivohomozygotization assay. <i>Mutagenesis</i> , 2016, 31, 417-424.	1.0	5
87	Synthesis and in vitro anticancer activity of new 2-thioxo-oxazolidin-4-one derivatives. <i>Pharmacological Reports</i> , 2017, 69, 633-641.	1.5	9
88	New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 379-397.	2.6	19
89	Identification of a Triterpenoid as a Novel PPAR γ Activator Derived from Formosan Plants. <i>Phytotherapy Research</i> , 2017, 31, 1722-1730.	2.8	9
90	TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPAR γ -SIRT1 feedback loop in human bladder cancer cells. <i>Cancer Letters</i> , 2018, 414, 278-293.	3.2	58
91	Enteric Microbiotaâ€“Gutâ€“Brain Axis from the Perspective of Nuclear Receptors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2210.	1.8	21
92	New insights into sperm with total globozoospermia: Increased fatty acid oxidation and centrin1 alteration. <i>Systems Biology in Reproductive Medicine</i> , 2019, 65, 390-399.	1.0	24

#	ARTICLE	IF	CITATIONS
93	Immunometabolism of Phagocytes During Mycobacterium tuberculosis Infection. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 105.	1.6	65
94	Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. <i>Genes</i> , 2019, 10, 709.	1.0	71
95	Cycloaddition reactions for antiviral compounds. , 2019, , 1-83.		3
96	Peroxisome Proliferator-Activated Receptors as Molecular Links between Caloric Restriction and Circadian Rhythm. <i>Nutrients</i> , 2020, 12, 3476.	1.7	15
97	Peroxisome Proliferator-Activated Receptors and Caloric Restrictionâ€™Common Pathways Affecting Metabolism, Health, and Longevity. <i>Cells</i> , 2020, 9, 1708.	1.8	39
98	Extremely Lowâ€™Frequency Electromagnetic Field Altered PPAR γ and CCL2 Levels and Suppressed CD44 + / CD24 α^+ Breast Cancer Cells Characteristics. <i>Bulletin of the Korean Chemical Society</i> , 2020, 41, 812-823.	1.0	6
99	Host-Directed Therapy in Tuberculosis: Targeting Host Metabolism. <i>Frontiers in Immunology</i> , 2020, 11, 1790.	2.2	17
100	Role of Transmembrane 4 L Six Family 1 in the Development and Progression of Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 202.	1.6	25
101	Identifying kinase targets of PPAR γ in human breast cancer. <i>Journal of Drug Targeting</i> , 2021, 29, 660-668.	2.1	2
102	Thiazolidinedione â€™Magic Bulletsâ€™Simultaneously Targeting PPAR γ and HDACs: Design, Synthesis, and Investigations of their <i>In Vitro</i> and <i>In Vivo</i> Antitumor Effects. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6949-6971.	2.9	20
103	Rosiglitazone Alleviates Mechanical Allodynia of Rats with Bone Cancer Pain through the Activation of PPAR γ to Inhibit the NF- κ B/NLRP3 Inflammatory Axis in Spinal Cord Neurons. <i>PPAR Research</i> , 2021, 2021, 1-18.	1.1	11
104	Structural Insights into the Loss-of-Function R288H Mutant of Human PPAR γ . <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 1196-1201.	0.6	1
105	Effects of Ppar γ 1 deletion on late-stage murine embryogenesis and cells that undergo endocycle. <i>Developmental Biology</i> , 2021, 478, 222-235.	0.9	2
106	Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. <i>Thrombosis and Haemostasis</i> , 2005, 93, 810-815.	1.8	22
107	Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.. <i>Acta Biochimica Polonica</i> , 2008, 55, 75-84.	0.3	6
108	Synthesis, Spectroscopic, In-vitro and Computational Analysis of Hydrazones as Potential Antituberculosis Agents: (Part-I). <i>Combinatorial Chemistry and High Throughput Screening</i> , 2020, 23, 392-401.	0.6	25
109	Peroxisome proliferator-activated receptor- γ 34C>G polymorphism and colorectal cancer risk: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2010, 16, 2170.	1.4	13
110	A comparison of peroxisome proliferator-activated receptor- γ agonist and antagonist on human umbilical vein endothelial cells angiogenesis. <i>Advanced Biomedical Research</i> , 2013, 2, 54.	0.2	5

#	ARTICLE	IF	CITATIONS
111	Peroxisome proliferator-activated receptor $\hat{3}$ and colorectal cancer. World Journal of Gastrointestinal Oncology, 2010, 2, 159.	0.8	36
112	The Effects of Combined Treatment with an HMG-CoA Reductase Inhibitor and PPAR $\hat{3}$ Agonist on the Activation of Rat Pancreatic Stellate Cells. Gut and Liver, 2012, 6, 262-269.	1.4	6
113	Peroxisome Proliferator-Activated Receptor-Gamma Pro12Ala Polymorphism Could be a Risk Factor for Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2333-2340.	0.5	6
114	Peroxisome Proliferator-Activated Receptor (PPAR)., 2016, , 1-7.		0
115	Peroxisome Proliferator-Activated Receptor (PPAR)., 2018, , 3884-3890.		0
116	PPAR $\hat{3}$ Agonists in Combination Cancer Therapies. Current Cancer Drug Targets, 2020, 20, 197-215.	0.8	11
117	Nitro Fatty Acids (NO ₂ -FAs): An Emerging Class of Bioactive Fatty Acids. Molecules, 2021, 26, 7536.	1.7	9
118	Multi-targeted HDAC Inhibitors as Anticancer Agents: Current Status and Future Prospective. Current Medicinal Chemistry, 2023, 30, 2762-2795.	1.2	7
120	A Gold(III) Complex with Potential Anticancer Properties. ChemistrySelect, 2022, 7, .	0.7	3
121	Anticancer heterocyclic hybrids: design, synthesis, molecular docking and evaluation of new thiazolidinone-pyrazoles. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2023, 78, 1-16.	0.3	1